While immunotherapy has been established as the first-line option for treatment-naïve metastatic melanoma patients, including those harboring a BRAF mutation [92,93,94], patients who progress on a targeted therapy and later on immunotherapy, or the inverse order, still have limited treatment options and poor prognosis [88,96,97,98,99,100]. Here, BRAF is linked to metastatic melanoma.